Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: Prognostic impact

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 649-657

  Park, Sin Young ^a   Roh, Sang Jae ^a   Kim, Yo Na ^a   Kim, Sung Zoo ^a   Park, Ho Sung ^a   Jang, Kyu Yun ^a   Chung, Myoung Ja ^a   Kang, Myoung Jae ^a   Lee, Dong Geun ^a   Moon, Woo Sung ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Cholangiocarcinoma; Immunohistochemistry; Mucin

Indexed keywords

MUCIN 1; MUCIN 2; MUCIN 5AC; MUCIN 6; MUC1 PROTEIN, HUMAN; MUC2 PROTEIN, HUMAN; MUC5AC PROTEIN, HUMAN; MUC6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; BILE DUCT TUMOR; CHEMISTRY; INTRAHEPATIC BILE DUCT; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCIN 5AC; MUCIN-1; MUCIN-2; MUCIN-6; PROGNOSIS;

EID: 70349329737     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000485     Document Type: Article

References (34)

1. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR and Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51: 1-9, 2002.
2. Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125, 2004.
3. Dekker J, Rossen JW, Buller HA and Einerhand AW: The MUC family: an obituary. Trends Biochem Sci 27: 126-131, 2002.
4. Higuchi T, Orita T, Nakanishi S, Katsuya K, Watanabe H, Yamasaki Y, Waga I, Nanayama T, Yamamoto Y, Munger W, Sun HW, Falk RJ, Jennette JC, Alcorta DA, Li H, Yamamoto T, Saito Y and Nakamura M: Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem 279: 1968-1979, 2004.
5. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D and Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7: 209-221, 2002.
6. Gum JR Jr, Hicks JW, Gillespie AM, Carlson EJ, Komuves L, Karnik S, Hong JC, Epstein CJ and Kim YS: Goblet cell-specific expression mediated by the MUC2 mucin gene promoter in the intestine of transgenic mice. Am J Physiol 276: 666-676, 1999.
7. Horinouchi M, Nagata K, Nakamura A, Goto M, Takao S, Sakamoto M, Fukushima N, Miwa A, Irimura T and Imai K: Expression of different glycoforms of membrane mucin (MUC1) and secretory mucin (MUC2, MUC5AC and MUC6) in pancreatic neoplasms. Acta Histochem Cytochem 36: 443-453, 2003.
8. Kim YS and Gum JR Jr: Diversity of mucin genes, structure, function, and expression. Gastroenterology 109: 999-1001, 1995.
9. Kondo K, Kohno N, Yokoyama A and Hiwada K: Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res 58: 2014-2019, 1998.
10. Makiguchi Y, Hinoda Y and Imai K: Effect of MUC1 mucin, an anti-adhesion molecule, on tumor cell growth. Jpn J Cancer Res 87: 505-511, 1996.
11. Van de Wiel-van Kemenade E, Ligtenberg MJ, De Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J and Figdor CG: Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151: 767-776, 1993.
12. Hamilton SR and Aaltonen LA: Pathology and genetics of tumours of the digestive system. IARC press, Lyon, pp173-180, 2004.
13. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M: American Joint Committee on Cancer: Cancer Staging Manual. 6th edition. Springer-Verlag, pp131-138, 2002.
14. Yamashita K, Yonezawa S, Tanaka S, Shirahama H, Sakoda K, Imai K, Xing PX, McKenzie IF, Hilkens J and Kim YS: Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int J Cancer 55: 82-91, 1993.
15. Sasaki M and Nakanuma Y: Expression of mucin core protein of mammary type in primary liver cancer. Hepatology 20: 1192-1197, 1994.
16. Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS and Sato E: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 30: 1347-1355, 1999.
17. Tamada S, Goto M, Nomoto M, Nagata K, Shimizu T, Tanaka S, Sakoda K, Imai K and Yonezawa S: Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Patho Int 52: 713-723, 2002.
18. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A and Hilkens J: Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129: 255-265, 1995.
19. Wesseling J, van der Valk SW and Hilkens J: A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7: 565-577, 1996.
20. Suh KS, Chang SH, Lee HJ, Roh HR, Kim SH and Lee KU: Clinical outcomes and apomucin expression of intrahepatic cholangiocarcinoma according to gross morphology. J Am Coll Surg 195: 782-789, 2002.
21. Sasaki M, Nakanuma Y and Kim YS: Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: an immunohistochemical study. Hepatology 24: 1074-1078, 1996.
22. Boonla C, Wongkham S, Sheehan JK, Wongkham C, Bhudhisawasdi V, Tepsiri N and Pairojkul C: Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer 98: 1438-1443, 2003.
23. Wongkham S, Sheehan JK, Boonla C, Patrakitkomjorn S, Howard M, Kirkham S, Sripa B, Wongkham C and Bhudhisawasdi V: Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. Cancer Lett 195: 93-99, 2003.
24. Aishima S, Kuroda Y, Nishihara Y, Taguchi K, Taketomi A, Maehara Y and Tsuneyoshi M: Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behavior. Histopathology 49: 35-44, 2006.
25. Lee MJ, Lee HS, Kim WH, Choi Y and Yang M: Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 16: 403-410, 2003.
26. Bartman AE, Buisine MP, Aubert JP, Niehans GA, Toribara NW, Kim YS, Kelly EJ, Crabtree JE and Ho SB: The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues. J Pathol 186: 398-405, 1998.
27. Awaya H, Takeshima Y, Yamasaki M and Inai K: Expression of MUC1, MUC2, MUC5AC and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 121: 644-653, 2004.
28. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ and Li Y: MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 22: 565-573, 2005.
29. Matsukita S, Nomoto M, Kitajima S, Tanaka S, Goto M, Irimura T, Kim YS, Sato E and Yonezawa S: Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Histopathology 42: 26-36, 2003.
30. Lee HS, Lee HK, Kim HS, Yang HK and Kim WH: Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200: 39-46, 2003.
31. Chang HJ, Kim SW, Lee BL, Hong EK and Kim WH: Phenotypic alterations of mucins and cytokeratins during gallbladder carcinogenesis. Pathol Int 54: 576-584, 2004.
32. Thuwajit P, Chawengrattanachot W, Thuwajit C, Sripa B, Paupairoj A and Chau-In S: Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival. J Gastroenterol Hepatol 23: 771-778, 2008.
33. Esposito I and Schirmacher P: Pathological aspects of cholangiocarcinoma. HPB 10: 83-86, 2008.
34. Duval JV, Savas L and Banner BF: Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med 124: 1196-1200, 2000.